Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Simone Bonde Haastrup"'
Publikováno v:
Haastrup, S B, Hellfritzsch, M, Nybo, M, Hvas, A M & Grove, E L 2021, ' Real-world experience with reversal of dabigatran by idarucizumab ', Thrombosis Research, vol. 197, pp. 179-184 . https://doi.org/10.1016/j.thromres.2020.11.010
Haastrup, S B, Poulsen, M H, Nybo, M, Hvas, A-M & Grove, E L 2021, ' Real-world experience with reversal of dabigatran by idarucizumab ', Thrombosis Research, vol. 197, pp. 179-184 . https://doi.org/10.1016/j.thromres.2020.11.010
Haastrup, S B, Poulsen, M H, Nybo, M, Hvas, A-M & Grove, E L 2021, ' Real-world experience with reversal of dabigatran by idarucizumab ', Thrombosis Research, vol. 197, pp. 179-184 . https://doi.org/10.1016/j.thromres.2020.11.010
Aims Idarucizumab reverses the anticoagulant effect of dabigatran. We aimed to investigate real-world experience with idarucizumab and associated clinical outcomes. Methods We conducted a retrospective observational case series on dabigatran users tr
Autor:
Anton Pottegård, Erik Lerkevang Grove, Lotte Rasmussen, Maja Hellfritzsch, Simone Bonde Haastrup
Publikováno v:
Hellfritzsch, M, Pottegård, A, Haastrup, S B, Rasmussen, L & Grove, E L 2020, ' Cohort selection in register-based studies of direct oral anticoagulant users with atrial fibrillation : An inevitable trade-off between selection bias and misclassification ', Basic and Clinical Pharmacology and Toxicology, vol. 127, no. 1, pp. 3-5 . https://doi.org/10.1111/bcpt.13423
Hellfritzsch, M, Pottegård, A, Haastrup, S B, Rasmussen, L & Grove, E L 2020, ' Cohort selection in register-based studies of direct oral anticoagulant users with atrial fibrillation : An inevitable trade-off between selection bias and misclassification ', Basic & Clinical Pharmacology & Toxicology, vol. 127, no. 1, pp. 3-5 . https://doi.org/10.1111/bcpt.13423
Hellfritzsch, M, Pottegård, A, Haastrup, S B, Rasmussen, L & Grove, E L 2020, ' Cohort selection in register-based studies of direct oral anticoagulant users with atrial fibrillation : An inevitable trade-off between selection bias and misclassification ', Basic & Clinical Pharmacology & Toxicology, vol. 127, no. 1, pp. 3-5 . https://doi.org/10.1111/bcpt.13423
Autor:
Erik Lerkevang Grove, Maja Hellfritzsch, Lotte Rasmussen, Anton Pottegård, Simone Bonde Haastrup
Publikováno v:
Haastrup, S, Hellfritzsch, M, Rasmussen, L, Pottegård, A & Grove, E L 2018, ' Use of Non-Vitamin K Antagonist Oral Anticoagulants 2008-2016 : A Danish Nationwide Cohort Study ', Basic & Clinical Pharmacology & Toxicology, vol. 123, no. 4, pp. 452-463 . https://doi.org/10.1111/bcpt.13024
Haastrup, S B, Hellfritzsch, M, Rasmussen, L, Pottegård, A & Grove, E L 2018, ' Use of Non-Vitamin K Antagonist Oral Anticoagulants 2008-2016 : A Danish Nationwide Cohort Study ', Basic & Clinical Pharmacology & Toxicology, vol. 123, no. 4, pp. 452-463 . https://doi.org/10.1111/bcpt.13024
Haastrup, S B, Hellfritzsch, M, Rasmussen, L, Pottegård, A & Grove, E L 2018, ' Use of Non-Vitamin K Antagonist Oral Anticoagulants 2008-2016 : A Danish Nationwide Cohort Study ', Basic & Clinical Pharmacology & Toxicology, vol. 123, no. 4, pp. 452-463 . https://doi.org/10.1111/bcpt.13024
We aimed to provide detailed utilization data on the total use of non-vitamin K antagonist oral anticoagulants (NOACs) since their introduction in 2008. Using the nationwide Danish National Prescription Registry, we identified all individuals filling